<?xml version='1.0' encoding='utf-8' ?>



<rss version="2.0"
      xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/"
      xmlns:dc="http://purl.org/dc/elements/1.1/"
      xmlns:atom="http://www.w3.org/2005/Atom">
   <channel>
     <title><![CDATA[Govt.Medical College Central Library, Kottayam Search for 'au:&quot;Wolverton, Stephen E&quot;']]></title>
     <link>/cgi-bin/koha/opac-search.pl?q=ccl=au%3A%22Wolverton%2C%20Stephen%20E%22&amp;format=rss</link>
     <atom:link rel="self" type="application/rss+xml" href="/cgi-bin/koha/opac-search.pl?q=ccl=au%3A%22Wolverton%2C%20Stephen%20E%22&amp;sort_by=relevance_dsc&amp;format=atom"/>
     <description><![CDATA[ Search results for 'au:&quot;Wolverton, Stephen E&quot;' at Govt.Medical College Central Library, Kottayam]]></description>
     <opensearch:totalResults>3</opensearch:totalResults>
     <opensearch:startIndex>0</opensearch:startIndex>
     
       <opensearch:itemsPerPage>20</opensearch:itemsPerPage>
     
	 
     <atom:link rel="search" type="application/opensearchdescription+xml" href="/cgi-bin/koha/opac-search.pl?&amp;sort_by=&amp;format=opensearchdescription"/>
     <opensearch:Query role="request" searchTerms="" startPage="" />
     <item>
       <title>
    Comprehensive dermatologic drug therapy






</title>
       <dc:identifier>ISBN:</dc:identifier>
        
        <link>/cgi-bin/koha/opac-detail.pl?biblionumber=32166</link>
        
       <description><![CDATA[









	   <p>By Wolverton, Stephen E. 
	   Elsevier Inc. 2013
                        . 826
                        , I Introduction
1
II Important Drug Regulatory Issues
41
III Systemic Drugs for Infectious Diseases
61
IV Systemic Immunomodulatory and Antiproliferative Drugs
143
V Drugs Used in Conjunction with Ultraviolet or Visible Light
279
VI Biological Therapeutics
307
VII Miscellaneous Systemic Drugs
343
VIII Topical Drugs for Infectious Diseases
445
X Miscellaneous Topical Drugs
551
XI Injectable and Mucosal Routes of Drug Administration
637
XII Major Adverse Effects from Systemic Drugs
677
XIII Special Pharmacology and Therapeutic Topics
757
Appendix I Ten drugs of increasing importance to dermatology
787
Appendix II Dapsone patient education and informed consent
792
Subject Index
793
Copyright

IX Topical Immunomodulatory and Antiproliferative Drugs
487

                        
                        
       </p>

<p><a href="/cgi-bin/koha/opac-reserve.pl?biblionumber=32166">Place Hold on <em>Comprehensive dermatologic drug therapy</em></a></p>

						]]></description>
       <guid>/cgi-bin/koha/opac-detail.pl?biblionumber=32166</guid>
     </item>
	 
     <atom:link rel="search" type="application/opensearchdescription+xml" href="/cgi-bin/koha/opac-search.pl?&amp;sort_by=&amp;format=opensearchdescription"/>
     <opensearch:Query role="request" searchTerms="" startPage="" />
     <item>
       <title>
    Comprehensive dermatologic drug therapy






</title>
       <dc:identifier>ISBN:</dc:identifier>
        
        <link>/cgi-bin/koha/opac-detail.pl?biblionumber=32167</link>
        
       <description><![CDATA[









	   <p>By Wolverton, Stephen E. 
	   Elsevier Inc. 2013
                        
                        
                        
                        
       </p>

<p><a href="/cgi-bin/koha/opac-reserve.pl?biblionumber=32167">Place Hold on <em>Comprehensive dermatologic drug therapy</em></a></p>

						]]></description>
       <guid>/cgi-bin/koha/opac-detail.pl?biblionumber=32167</guid>
     </item>
	 
     <atom:link rel="search" type="application/opensearchdescription+xml" href="/cgi-bin/koha/opac-search.pl?&amp;sort_by=&amp;format=opensearchdescription"/>
     <opensearch:Query role="request" searchTerms="" startPage="" />
     <item>
       <title>
    Comprehensive dermatologic drug therapy






</title>
       <dc:identifier>ISBN:9780323612111</dc:identifier>
        
        <link>/cgi-bin/koha/opac-detail.pl?biblionumber=48977</link>
        
       <description><![CDATA[









	   <p>By Wolverton, Stephen E. 
	   Philadelphia Elsevier Inc. 2021
                        . 825p.
                        , Table of Contents
Part I: Introduction
1 Basic Principles of Pharmacology

2 Principles for Maximizing the Safety of Dermatologic Drug Therapy

3 Polymorphisms: Why Individual Drug Responses Vary

4 Adherence to Drug Therapy

5 Medical Decision Making

Part II: Important Drug Regulatory Issues

6 The FDA Drug Approval Process

7 Pharmacovigilance: Verifying that Drugs Remain Safe

8 Drugs Taken Off the Market: Important Lessons Learned

Part III: Systemic Drugs for Infectious Diseases

9 Systemic Antibacterial Agents

10 Systemic Antifungal Agents

11 Systemic Antiviral Agents

12 Systemic Antiparasitic Agents

Part IV: Systemic Immunomodulatory Drugs

13 Systemic Corticosteroids

14 Methotrexate

15 Azathioprine

16 Mycophenolates

17 Cyclosporine

18 Phosphodiesterase-4 and Janus Kinase Inhibitors

19 Cytotoxic Agents

20 Dapsone

21 Antimalarial Agents

22 Systemic Retinoids

Part V: Drugs Used in Conjunction with UV or Visible Light

23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities

24 Extracorporeal Photochemotherapy (Photopheresis)

25 Photodynamic Therapy

Part VI: Biologic Therapeutics

26 Tumor Necrosis Factor Inhibitors

27 Interleukin 12/23 Inhibitors

28 Interleukin 17 Inhibitors

29 Interleukin 23 Inhibitors

30 Rituximab

31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, Others

Part VII: Miscellaneous Systemic Drugs

32 Antihistamines

33 Vasoactive and Antiplatelet Agents

34 Antiandrogens and Androgen Inhibitors

35 Psychotropic Agents

36 Intravenous Immunoglobulin Therapy

37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events

38 Hedgehog Pathway Inhibitors

39 Drugs for the Skinternist

40 Miscellaneous Systemic Drugs

Part VIII: Topical Drugs for Infectious Diseases

41 Topical Antibacterial Agents

42 Topical Antifungal Agents

43 Topical and Intralesional Antiviral Agents

44 Topical Antiparasitic Agents

Part IX: Topical Immunomodulatory Drugs

45 Topical Corticosteroids

46 Topical Retinoids

47 Topical and Intralesional Chemotherapeutic Agents

48 Topical Calcineurin Inhibitors

49 Topical Vitamin D3

Part X: Miscellaneous Topical Drugs

50 Sunscreens

51 Therapeutic Shampoos

52 a-Hydroxy Acids

53 Chemical Peels

54 Products for the Care of Chronic Wounds

55 Agents Used for Treatment of Hyperkeratosis

56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents

57 Miscellaneous Topical Agents

Part XI: Injectable and Mucosal Routes of Drug Administration

58 Local Anesthetics

59 Injectable Dermal and Subcutaneous Fillers

60 Botulinum Toxin Injections

61 Oral Mucosal Therapeutics

Part XII: Major Adverse Effects From Systemic Drugs

62 Hepatotoxicity of Dermatologic Drug Therapy

63 Hematologic Toxicity of Drug Therapy

64 Drug-induced Malignancy

65 Dermatologic Drugs During Pregnancy and Lactation

66 Drug Interactions

67 Cutaneous Drug Reactions With Systemic Features

Part XIII: Special Pharmacology and Therapeutics Topics

68 Informed Consent and Risk Management

69 Compounding in Dermatology

70 Dermatologic Drug Therapy in Children

Appendix I Core Questions for Understanding Systemic Dermatologic Drugs

Appendix II The Most Potentially Serious Drug Interactions
                        
                         9780323612111
       </p>

<p><a href="/cgi-bin/koha/opac-reserve.pl?biblionumber=48977">Place Hold on <em>Comprehensive dermatologic drug therapy</em></a></p>

						]]></description>
       <guid>/cgi-bin/koha/opac-detail.pl?biblionumber=48977</guid>
     </item>
	 
   </channel>
</rss>





